Oral administration of genetically modifiedBifidobacteriumdisplaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice

More than 170 million people worldwide are chronic HCV (Hepatitis C virus) carriers, and about 30% of them will develop progressive liver disease, such as cirrhosis and hepatocellular carcinoma. A combination of pegylated interferon-[alpha] with ribavirin, the standard treatment for HCV infection, h...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-05, Vol.32 (25), p.3066
Hauptverfasser:	Takei, Saki, Omoto, Chika, Kitagawa, Koichi, Morishita, Naoya, Katayama, Takane, Shigemura, Katsumi, Fujisawa, Masato, Kawabata, Masato, Hotta, Hak, Shirakawa, Toshiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Bacteria E coli Genetic engineering Genotype & phenotype Immune response Infections Interferon Liver cirrhosis Peptides Probiotics Proteins Salmonella Science Technological change Vaccines Yogurt
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!